Device Trial Radar · NCT03409120
Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
Last checked: Nov 20, 2026Latest source record: Nov 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jan 1, 2018
Primary completion
Jun 30, 2021
Study completion Jun 30, 2022
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research
- First posted
- Jan 24, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study occurs during five visits that are already scheduled as part of "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688). If participants have dystonia associated with Parkinson's disease, the investigators will consent and administer one additional rating scale (Burke-Fahn-Marsden Dystonia Rating Scale) to assess the severity of dystonia.
Conditions
- Dystonia-Parkinsonism, Adult-Onset
- Parkinson Disease
Interventions
Boston Scientific Vercise PC IPG with directional DBS leadDevice
We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Burke-Fahn-Marsden Dystonia Rating ScaleTime frame: 5 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.